Concepción Nicolás
YOU?
Author Swipe
View article: Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO
Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO Open
Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) remains challenging to treat, especially in patients ineligible for intensive therapy or chimeric antigen receptor T cells. Tafasitamab plus lenalidomide (T/L) is an effective o…
View article: Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic Lymphoma
Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic Lymphoma Open
Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous disease characterized by a limited number of molecularly defined subtypes. Recently, genomic-based algorithms have been proposed for the classification of this disease. The whole exo…
View article: Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)
Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO) Open
Introduction Therapy of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) remains challenging, particularly for ineligible patients for intensive therapy. Tafasitamab-lenalidomide (T/L) represents an effective treatment opti…
View article: Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo
Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo Open
Background: HGBCL, with or without MYC, BCL2 and/or BCL6 rearrangements, constitute approximately 10-15% of diffuse large B-cell lymphomas (DLBCL). Most cases are diagnosed at advanced stages with associated poor prognosis and tend to be t…
View article: Genetic Subtyping Using Whole Exome Sequencing across Large B Cell Lymphoma Entities in a Series of 109 DLBCL and Plasmablastic Lymphoma Cases
Genetic Subtyping Using Whole Exome Sequencing across Large B Cell Lymphoma Entities in a Series of 109 DLBCL and Plasmablastic Lymphoma Cases Open
Background: Diffuse Large B Cell Lymphomas are still a significantly heterogeneous disease with few molecularly defined entities. Recently genomic based algorithms have been proposed for DBCL NOS disease classification, including the Lymph…
View article: Ureaplasma parvum Septic Arthritis, a Clinic Challenge
Ureaplasma parvum Septic Arthritis, a Clinic Challenge Open
Ureaplasma parvum is usually part of the normal genital microbiota. Rarely, it can cause invasive infections such as septic arthritis or meningitis. A case of a 74-year-old woman with follicular lymphoma who developed cellulitis followed b…
View article: The Value of Adding Surveillance Cultures to Fluoroquinolone Prophylaxis in the Management of Multiresistant Gram Negative Bacterial Infections in Acute Myeloid Leukemia
The Value of Adding Surveillance Cultures to Fluoroquinolone Prophylaxis in the Management of Multiresistant Gram Negative Bacterial Infections in Acute Myeloid Leukemia Open
Multidrug resistant Gram-Negative Bacterial Infections (MR-GNBI) are an increasing cause of mortality in acute myeloid leukemia (AML), compromising the success of antineoplastic therapy. We prospectively explored a novel strategy, includin…
View article: Rituximab, interferon‐alfa‐2b and dose dense <scp>CVP</scp> is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the <scp>LNH</scp>‐<scp>PRO</scp>‐05 study
Rituximab, interferon‐alfa‐2b and dose dense <span>CVP</span> is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the <span>LNH</span>‐<span>PRO</span>‐05 study Open
The use of drugs with both antiproliferative and immune effects in the treatment of patients with follicular lymphoma (FL) has significantly improved disease control and survival, and is nowadays the backbone of treatment. Currently, ritux…
View article: Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma
Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma Open
To the editor:
Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue (MALT) present in most cases as localized disease and can be successfully treated with local therapies or antibiotics.[1][1][⇓][2][⇓][3]-[4][4] …
View article: Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia
Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia Open
Significance Relapsed acute lymphoblastic leukemia (ALL) is associated with chemotherapy resistance and poor prognosis. This study analyzes the emergence of acquired mutations in relapsed ALL samples, identifying genes implicated in diseas…